Analysen von Matthew Weston

15.01.24 Sartorius vz. Neutral UBS AG
15.01.24 Roche Neutral UBS AG
15.01.24 Novartis Buy UBS AG
18.04.23 Sartorius vz. Neutral Credit Suisse Group
07.06.22 AstraZeneca Outperform Credit Suisse Group
06.08.21 Merck Outperform Credit Suisse Group
14.12.20 AstraZeneca Outperform Credit Suisse Group
06.11.20 AstraZeneca Outperform Credit Suisse Group
16.10.20 Roche Neutral Credit Suisse Group
08.10.20 Roche Neutral Credit Suisse Group
24.07.20 Roche Neutral Credit Suisse Group
15.05.20 Merck Outperform Credit Suisse Group
23.04.20 Roche Neutral Credit Suisse Group
18.02.20 AstraZeneca Outperform Credit Suisse Group
25.11.19 Novartis Neutral Credit Suisse Group
29.10.19 AstraZeneca Outperform Credit Suisse Group
25.04.19 Novartis Neutral Credit Suisse Group
05.04.19 Novartis Neutral Credit Suisse Group
25.02.19 Roche Neutral Credit Suisse Group
15.02.19 AstraZeneca Outperform Credit Suisse Group
31.01.19 Novartis Neutral Credit Suisse Group
28.01.19 Roche Neutral Credit Suisse Group
09.11.18 AstraZeneca Outperform Credit Suisse Group
19.10.18 Novartis Neutral Credit Suisse Group
18.10.18 Roche Underperform Credit Suisse Group
30.08.18 AstraZeneca Outperform Credit Suisse Group
09.08.18 Novo Nordisk Neutral Credit Suisse Group
30.07.18 AstraZeneca Outperform Credit Suisse Group
27.07.18 Roche Underperform Credit Suisse Group
19.07.18 Novartis Neutral Credit Suisse Group
12.06.18 AstraZeneca Outperform Credit Suisse Group
25.05.18 AstraZeneca Outperform Credit Suisse Group
25.05.18 Roche Underperform Credit Suisse Group
20.04.18 Novartis Underperform Credit Suisse Group
18.04.18 Roche Neutral Credit Suisse Group
24.01.18 Novartis Neutral Credit Suisse Group
25.01.18 Novartis Underperform Credit Suisse Group
31.10.16 Novo Nordisk Neutral Credit Suisse Group
08.08.16 Novo Nordisk Neutral Credit Suisse Group
20.05.15 Merck Outperform Credit Suisse Group
19.10.11 Merck neutral Credit Suisse Group
28.07.11 Merck neutral Credit Suisse Group